Applications of Activated Carbon in the Pharmaceutical Field

Activated Carbon (AC) is a porous carbon material prepared by high-temperature carbonization and activation. Boasting an ultra-high specific surface area of 950–2000 m²/g, a hierarchical pore structure, and non-specific adsorption capacity, it has become one of the most widely used physical adsorbents in the pharmaceutical field. From the use of charcoal for healing recorded in the Egyptian Papyrus around 1550 BC to modern clinical applications in poisoning first aid, wound care, blood purification, and drug delivery, Medicinal Activated Carbon has proven its therapeutic value over thousands of years, forming a mature application system covering first aid, chronic diseases, surgery, and other scenarios. According to market data, the global pharmaceutical-grade activated carbon market reached USD 2.1 billion in 2023 and is expected to exceed USD 4.5 billion by 2032, with a compound annual growth rate (CAGR) of 8.5%, making it one of the fastest-growing segments in the pharmaceutical materials sector.

 

 

Ⅰ. Core Properties and Quality Standard System of Pharmaceutical-Grade Activated Carbon

 

1. Core Adsorption Properties and Raw Material Differentiation

The performance of Pharmaceutical Activated Carbon stems from its controllable pore structure: micropores (pore size < 2 nm) adsorb small-molecule toxins (e.g., drugs, organic poisons); mesopores (2–50 nm) are suitable for protein-based inflammatory factors and middle-molecular uremic toxins; macropores (> 50 nm) serve as diffusion channels for adsorbates. Activated carbons prepared from different raw materials exhibit significant performance differences: coconut shell-based activated carbon features well-developed micropores, low ash content, and high purity, making it the preferred raw material for oral detoxification and pharmaceutical excipients; coal-based activated carbon has a high mesopore ratio, ideal for middle and large-molecule adsorption in hemoperfusion; wood and bamboo-based activated carbons offer excellent biocompatibility, commonly used in wound dressings and medical fiber preparation.

Recent breakthroughs in nanocarbon technology have further expanded its pharmaceutical applications: nanocarbon particles with a particle size of approximately 150 nm can selectively enter the lymphatic system without entering blood vessels, serving as a core material for precise lymphatic tracing in oncological surgery and completely addressing the poor targeting issue of traditional tracers.

 

2. Globally Unified Medical-Grade Quality Control System

Pharmaceutical Activated Carbon has far higher safety requirements than industrial-grade products, with strict quality standards established in pharmacopoeias worldwide. The Chinese Pharmacopoeia (2025 Edition) stipulates that Pharmaceutical Activated Carbon must meet the following criteria: neutral pH, chloride content ≤ 0.1%, sulfate content ≤ 0.05%, ignition residue ≤ 3%, heavy metal content ≤ 10 ppm, and methylene blue adsorption capacity of 25 mL of 0.1% methylene blue solution completely adsorbed per 0.3 g of activated carbon. It must also pass microbial limit and bacterial endotoxin tests. The U.S. Pharmacopeia (USP) and European Pharmacopeia (EP) additionally require tests for extractable impurities, cytotoxicity, and blood compatibility, and Activated carbon for injection required to pass hemolysis tests to ensure no blood cell damage or immunogenicity.

Medicinal activated carbon must also satisfy five key clinical safety requirements: no damage to blood cells, no inflammatory or allergic reactions, no carcinogenicity, no release of toxic impurities, and no adsorption of essential nutrients and metabolites in the human body-these are the core thresholds distinguishing it from ordinary industrial activated carbon.

 

 

Ⅱ. Core Clinical Applications and Technical Practices of Pharmaceutical-Grade Activated Carbon

 

1. Acute Poisoning First Aid: The Clinically Preferred Non-Specific Antidote

Oral activated carbon is a first-line treatment recommended by global clinical guidelines for acute poisoning. Its detoxification mechanism involves binding to toxic molecules in the gastrointestinal tract via van der Waals forces and hydrophobic interactions, blocking their absorption and ultimately eliminating them through feces. The American Academy of Clinical Toxicology (AACT) and European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) explicitly specify: oral activated carbon is most effective within 1 hour of poisoning, with a single adult dose of 50–100 g and a pediatric dose of 1 g/kg body weight; for toxins with enterohepatic circulation (e.g., carbamazepine, theophylline, phenobarbital), a multi-dose regimen of 12.5–25 g every 2–4 hours is administered until toxin elimination.

Activated carbon adsorbs most organic poisons and some inorganic poisons, covering over 90% of common poisoning types, including sedative-hypnotics, analgesics, antidepressants, pesticides, and alkaloids. However, it has weak adsorption capacity for alcohols, iron supplements, lithium salts, strong acids, strong bases, and cyanides, and clinical misuse should be avoided. For paraquat poisoning with an extremely high mortality rate, activated carbon is the only proven effective adsorbent. Clinically, the "white + black regimen" is adopted: 30 g of activated carbon dissolved in mannitol solution for oral administration, combined with activated carbon hemoperfusion initiated within 6 hours of poisoning, which increases paraquat clearance by 5–7 times compared to hemodialysis, significantly prolonging patient survival.

 

2. Chronic Wound Care: Core Solution for Infection Control and Odor Management

Activated carbon dressings are revolutionary products in chronic wound treatment. Their mechanisms of action include: adsorbing wound exudate, bacterial metabolites, and necrotic tissue via a porous structure to reduce wound maceration; adsorbing volatile fatty acids and amines to completely eliminate foul odor from diabetic foot ulcers, pressure ulcers, and malignant wounds; creating a moist and breathable wound microenvironment to promote granulation tissue growth while blocking external microbial invasion.

A 2024 randomized controlled trial showed that for patients with diabetic foot ulcers, activated carbon cloth dressings reduced wound area by an average of 85.4% and achieved a complete healing rate of 30% after 8 weeks of treatment, significantly outperforming traditional silver dressings (65.1% reduction and 10% healing rate). Currently, mainstream silver-containing activated carbon dressings (e.g., Actisorb, Invasorb) combine the adsorption capacity of activated carbon with the antibacterial effect of silver ions, achieving a 99% inhibition rate against drug-resistant bacteria such as MRSA and Pseudomonas aeruginosa, and have become the standard treatment for diabetic foot ulcers, venous ulcers, and burn wounds. For intractable foul odor from advanced malignant ulceration, activated carbon dressings reduce odor intensity by over 80% within 24 hours, significantly improving patients' quality of life.

 

3. Blood Purification: Expansion from Poisoning First Aid to Critical Care Support

Hemoperfusion is a core application of activated carbon in critical care medicine, involving passing anticoagulated blood through an adsorption column filled with activated carbon to remove circulating toxins and inflammatory factors. Early uncoated activated carbon was prone to shedding microparticles, causing vascular embolism. Modern technologies, including modification with albumin, cellulose, and acrylic resin coatings, have completely resolved blood compatibility issues while retaining over 90% adsorption capacity.

Currently, activated carbon hemoperfusion cartridges are used in three major clinical scenarios: first, acute poisoning first aid, with higher clearance efficiency than hemodialysis for lipid-soluble and highly protein-bound toxins; second, middle-molecular uremic toxin removal in uremia, effectively adsorbing β2-microglobulin, parathyroid hormone, and other toxins unremovable by conventional dialysis, reducing dialysis complications; third, treatment of sepsis and multiple organ failure, adsorbing pro-inflammatory factors such as TNF-α and IL-6 to mitigate organ damage from inflammatory storms. The latest molecularly imprinted activated carbon technology enables specific adsorption of target toxins, significantly reducing non-specific clearance of beneficial substances, and has become a research direction for next-generation blood purification materials.

 

4. Chronic Kidney Disease: An Innovative Therapeutic Approach for Intestinal Detoxification

Oral spherical activated carbon AST-120 (brand name: Kremezin) represents a major breakthrough in non-dialysis treatment for chronic kidney disease (CKD). With a particle size of 0.2–0.4 mm, it selectively adsorbs uremic toxins such as indoxyl sulfate and p-cresyl sulfate in the intestine, blocks their enterohepatic circulation, reduces blood toxin levels, and delays renal function decline.

Clinical studies confirm that a daily dose of 6 g of AST-120 reduces the rate of renal function decline by 40% in early CKD patients, delaying dialysis initiation by 1–2 years. Additionally, AST-120 repairs the damaged intestinal barrier in CKD patients, reducing endotoxin entry into the bloodstream and systemic inflammation. It has been approved as an adjuvant treatment for early and mid-stage CKD in countries including Japan and China, marking a landmark product for activated carbon's expansion from first aid to chronic disease applications.

 

5. Oncological Surgery: Lymphatic Tracing and Precise Drug Delivery

Nanocarbon suspension injection is a core medical consumable independently developed in China for oncological surgery, leveraging the lymphatic targeting of nanocarbon to enable precise lymph node tracing during surgery. In gastric, thyroid, and colorectal cancer surgeries, nanocarbon injected around the tumor stains draining lymph nodes black within 5–10 minutes, increasing lymph node detection rates by over 30%. Meanwhile, it protects the parathyroid gland via "negative imaging", reducing parathyroid accidental resection rates by 60% in thyroid surgery. The 2025 Expert Consensus on the Application of Nanocarbon Tracing Technology in Gastrointestinal Oncological Surgery has listed it as a recommended technique for radical oncological surgery, with annual usage exceeding 500,000 cases nationwide.

In drug delivery, activated carbon's high porosity makes it an ideal drug carrier, enabling sustained and targeted drug delivery: 5-fluorouracil-loaded activated carbon for transarterial chemoembolization of hepatocellular carcinoma releases drugs locally in tumors continuously, reducing systemic side effects; oral activated carbon formulations loaded with ibuprofen or paracetamol achieve stable drug release for 12 hours, reducing administration frequency; surface-modified activated carbon nanoparticles enable pH-responsive drug release, precisely releasing chemotherapeutic drugs in the acidic tumor microenvironment, making them a research hotspot for anticancer drug delivery.

 

 

Ⅲ. Technical Bottlenecks and Progress in Modification Research

Although the application of Pharmaceutical Activated Carbon has been quite mature, three core technical bottlenecks remain: first, non-specific adsorption, which readily adsorbs nutrients and concomitant medications while removing toxins; second, blood compatibility and cytotoxicity, with unmodified activated carbon prone to platelet aggregation and microembolism upon blood contact; third, poor palatability of oral formulations, with taste issues and tooth staining reducing patient compliance, especially among children. 

To address these issues, three major modification directions have emerged globally:

• Precise pore size regulation and molecular imprinting technology: Template-based preparation of activated carbon with specific pore sizes and surface groups enables selective adsorption of target toxins, significantly reducing non-specific adsorption.
• Biocompatible surface modification: Grafting hydrophilic polymers such as polyethylene glycol (PEG) and chitosan reduces protein adsorption and platelet activation. Core-shell structured activated carbon completely isolates carbon particles from blood contact while retaining adsorption capacity.
• Oral formulation improvement: Microencapsulation of activated carbon particles combined with flavoring agents and dispersible tablet formulations completely resolves palatability issues. New formulations such as activated carbon biscuits and suspensions have entered clinical use.

 

In the future, the application of medicinal activated carbon will continue to expand further. As a professional manufacturer of activated carbon, we have a series of medicinal activated carbon. If you have this need and are interested in learning more, please feel free to contact us! 

Contact now